NIH awards $48.6M for biodefense drug development, with 13 bids indicating strong competition

Contract Overview

Contract Amount: $48,577,807 ($48.6M)

Contractor: Venatorx Pharmaceuticals Inc

Awarding Agency: Department of Health and Human Services

Start Date: 2016-09-19

End Date: 2026-03-31

Contract Duration: 3,480 days

Daily Burn Rate: $14.0K/day

Competition Type: FULL AND OPEN COMPETITION

Number of Offers Received: 13

Pricing Type: COST PLUS FIXED FEE

Sector: R&D

Official Description: IGF::OT::IGF - ORALLY BIOAVAILABLEβ-LACTAM/β-LACTAMASE INHIBITOR COMBINATION FOR BIODEFENSE AND PUBLIC HEALTH.

Place of Performance

Location: MALVERN, CHESTER County, PENNSYLVANIA, 19355

State: Pennsylvania Government Spending

Plain-Language Summary

Department of Health and Human Services obligated $48.6 million to VENATORX PHARMACEUTICALS INC for work described as: IGF::OT::IGF - ORALLY BIOAVAILABLEβ-LACTAM/β-LACTAMASE INHIBITOR COMBINATION FOR BIODEFENSE AND PUBLIC HEALTH. Key points: 1. Contract awarded for critical biodefense and public health research. 2. Strong competition suggests potential for competitive pricing. 3. Long contract duration indicates a significant, multi-year research effort. 4. Focus on R&D in Biotechnology aligns with national health security priorities. 5. Contract type (Cost Plus Fixed Fee) is common for complex research projects. 6. Geographic location in Pennsylvania may have local economic implications.

Value Assessment

Rating: good

The contract value of $48.6 million over approximately 9.6 years (3480 months) represents a significant investment in biodefense research. Benchmarking this against similar R&D contracts in biotechnology is challenging without more specific data on the scope and complexity of the research. However, the number of bidders (13) suggests a competitive environment that likely influenced the final pricing. The Cost Plus Fixed Fee structure is typical for research where costs can be variable, but the fixed fee component provides some cost control.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

The contract was awarded under full and open competition, with 13 bids received. This high level of competition is a positive indicator, suggesting that multiple capable vendors were interested and able to bid on this requirement. A robust competitive process generally leads to better price discovery and can drive innovation as contractors vie for the award.

Taxpayer Impact: For taxpayers, the strong competition means that the government likely received a more favorable price than it might have under a less competitive scenario. It also increases the likelihood that the funds are being used efficiently to secure the best research capabilities.

Public Impact

The primary beneficiaries are public health and national security, through the development of novel treatments for biodefense threats. The contract supports advanced research and development in biotechnology, specifically focusing on orally bioavailable beta-lactam/beta-lactamase inhibitor combinations. The geographic impact is primarily in Pennsylvania, where Venatorx Pharmaceuticals Inc. is located, potentially creating or sustaining high-skilled jobs in the region. The project advances scientific knowledge and capabilities within the biotechnology sector, contributing to the nation's preparedness for public health emergencies.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Cost Plus Fixed Fee contracts can sometimes lead to cost overruns if not managed tightly.
The long duration of the contract requires sustained oversight to ensure progress and adherence to objectives.
Reliance on a single contractor for this critical research area could pose a risk if performance falters.

Positive Signals

Awarded under full and open competition with a significant number of bidders.
Focus on a critical area of biodefense and public health preparedness.
Contractor has a defined role in developing essential medical countermeasures.

Sector Analysis

The contract falls within the Research and Development in Biotechnology sector (NAICS 541711), a critical area for national security and public health. This sector is characterized by high innovation, significant investment, and long development cycles. The market size for biodefense and novel antibiotic development is substantial, driven by ongoing threats from infectious diseases and antimicrobial resistance. This contract represents a specific investment within that broader market, aiming to address a particular class of biodefense threats.

Small Business Impact

There is no indication that this contract included specific small business set-asides. Given the specialized nature of biopharmaceutical R&D, large, established firms or those with specific technological expertise are often the primary bidders. Subcontracting opportunities for small businesses may exist, but are not explicitly detailed in the provided data. The overall impact on the small business ecosystem is likely minimal unless Venatorx Pharmaceuticals Inc. actively engages them.

Oversight & Accountability

Oversight for this contract would primarily fall under the Department of Health and Human Services (HHS) and the National Institutes of Health (NIH). As a Cost Plus Fixed Fee contract, rigorous financial oversight is expected to monitor expenditures against the approved budget and ensure the fixed fee is earned appropriately. Performance metrics and milestones would be key to assessing progress and accountability. Transparency is generally maintained through contract awards databases and agency reporting, though specific research progress details may be proprietary.

Related Government Programs

Biodefense Medical Countermeasures
National Institutes of Health Research Grants
Antimicrobial Resistance Initiatives
Biotechnology Research and Development
Department of Health and Human Services Contracts

Risk Flags

Long contract duration requires sustained oversight.
Cost Plus Fixed Fee structure necessitates careful cost monitoring.
Potential for scientific obsolescence over the contract term.

Frequently Asked Questions

What is this federal contract paying for?

Department of Health and Human Services awarded $48.6 million to VENATORX PHARMACEUTICALS INC. IGF::OT::IGF - ORALLY BIOAVAILABLEβ-LACTAM/β-LACTAMASE INHIBITOR COMBINATION FOR BIODEFENSE AND PUBLIC HEALTH.

Who is the contractor on this award?

The obligated recipient is VENATORX PHARMACEUTICALS INC.

Which agency awarded this contract?

Awarding agency: Department of Health and Human Services (National Institutes of Health).

What is the total obligated amount?

The obligated amount is $48.6 million.

What is the period of performance?

Start: 2016-09-19. End: 2026-03-31.

What is the specific biodefense threat this research aims to address?

The contract specifically targets the development of orally bioavailable $\beta$-lactam/$\beta$-lactamase inhibitor combinations. This class of drugs is crucial for combating bacterial infections, particularly those caused by Gram-negative bacteria that have developed resistance to existing antibiotics through the production of $\beta$-lactamase enzymes. These resistant infections pose a significant threat in both public health settings and as potential bioweapons. The focus on 'orally bioavailable' suggests an aim to create treatments that can be administered outside of a hospital setting, enhancing preparedness and response capabilities for widespread threats.

How does the Cost Plus Fixed Fee (CPFF) structure impact value for money?

The Cost Plus Fixed Fee (CPFF) contract structure is common for research and development where the scope of work can be uncertain and costs are difficult to predict precisely. In this model, the contractor is reimbursed for allowable costs incurred, plus a predetermined fixed fee representing profit. While CPFF provides flexibility for evolving research needs, it can present challenges for value-for-money assessment. The government bears the risk of cost overruns, although the fixed fee provides some predictability in profit. Effective oversight is crucial to ensure costs are reasonable and allocable, and that the fixed fee is commensurate with the contractor's effort and risk. The strong competition (13 bidders) suggests that even with this structure, competitive pressures likely influenced the initial fee and overall cost proposal.

What are the key performance indicators (KPIs) for this contract?

While specific KPIs are not detailed in the provided data, typical performance indicators for a biopharmaceutical R&D contract of this nature would likely include: achievement of specific research milestones (e.g., successful preclinical testing, formulation development, identification of lead compounds), adherence to project timelines, quality of research data generated, compliance with regulatory requirements (e.g., FDA guidelines), and effective management of project budget. The 'fixed fee' component of the CPFF contract implies that the contractor's ability to meet these performance expectations is directly tied to earning their profit. Regular progress reports and reviews by NIH would monitor these KPIs.

What is the historical spending trend for similar biodefense R&D contracts by NIH?

Historical spending by NIH on biodefense and related R&D has been substantial and generally increasing, driven by national security priorities and the growing threat of antimicrobial resistance. Agencies like the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, consistently fund research into emerging infectious diseases and medical countermeasures. While specific spending trends for 'orally bioavailable $\beta$-lactam/$\beta$-lactamase inhibitor combinations' are not readily available without deeper analysis, overall federal investment in antibiotic development and biodefense has seen significant fluctuations based on perceived threats and funding appropriations. This $48.6 million award is a notable investment within this ongoing effort.

What is the track record of Venatorx Pharmaceuticals Inc. in government contracting?

Venatorx Pharmaceuticals Inc. is a clinical-stage pharmaceutical company focused on infectious diseases. While the provided data shows this specific contract award, a comprehensive assessment of their track record would require examining their history across various federal agencies and contract types. Information on their previous government contracts, successful project completions, and any past performance issues would be necessary for a full evaluation. However, securing a large, multi-year contract from NIH under full and open competition suggests they possess the necessary qualifications and capabilities deemed competitive by the agency.

What are the potential risks associated with the long contract duration (approx. 9.6 years)?

The long duration of this contract (3480 months, equating to roughly 9.6 years) presents several potential risks. Firstly, scientific and technological landscapes can change rapidly; the initial research objectives might become outdated or superseded by new discoveries, requiring contract modifications or potentially reducing its relevance. Secondly, maintaining consistent oversight and engagement from the contracting agency (NIH) over such an extended period can be challenging due to personnel turnover and shifting agency priorities. Thirdly, there's a risk of 'contract creep' where the scope subtly expands over time without adequate re-evaluation of cost and benefit. Finally, the contractor's own stability and continued focus over nearly a decade are factors that require ongoing monitoring.

Industry Classification

NAICS: Professional, Scientific, and Technical Services › Scientific Research and Development Services › Research and Development in Biotechnology

Product/Service Code: RESEARCH AND DEVELOPMENT › N – Health R&D Services

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: BASIC RESEARCH

Solicitation ID: NIAIDDMIDNIHAI2015037

Offers Received: 13

Pricing Type: COST PLUS FIXED FEE (U)

Evaluated Preference: NONE

Contractor Details

Address: 30 SPRING MILL DR, MALVERN, PA, 19355

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $48,577,807

Exercised Options: $48,577,807

Current Obligation: $48,577,807

Actual Outlays: $15,995,836

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES PROCEDURES NOT USED

Cost or Pricing Data: YES

Timeline